In vitro activity of BRL 17421 against Haemophilus influenzae, Neisseria gonorrhoeae, and Branhamella catarrhalis.
BRL 17421, a novel beta-lactam antibiotic, was tested in vitro against fastidious gram-negative bacteria and compared with amoxicillin and amoxicillin plus clavulanic acid. The compound showed good activity against Haemophilus influenzae (range of minimal inhibitory concentrations, 0.2 to 1 microgram/ml), Neisseria gonorrhoeae (0.007 to 0.5 microgram/ml), and Branhamella catarrhalis (0.03 to 0.1 microgram/ml). BRL 17421 exhibited excellent stability against the TEM-type beta-lactamase of H. influenzae and N. gonorrhoeae, and its activity was little affected by inoculum size. Minimal lethal concentrations of BRL 17421 for 10(7) colony-forming units of H. influenzae ranged between 0.5 and 4 micrograms/ml.
D000658:Amoxicillin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000201:enzymology; D019818:Clavulanic Acid; D006193:Haemophilus influenzae / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D009346:Neisseriaceae / Q000187:drug effects*; D010406:Penicillins / Q000494:pharmacology*; D001618:beta-Lactamases / Q000096:biosynthesis; D047090:beta-Lactams / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D010406:Penicillins; D047090:beta-Lactams; C031367:temocillin; D019818:Clavulanic Acid; D000658:Amoxicillin; D001618:beta-Lactamases